Performance of Wider system susceptibility testing with routine Enterobacteriaceae isolatesa
Antimicrobial agentb | % MICs obtained with Wider system within indicated log2 reference MIC: | % Essential Agreement | % Errors | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
>−2 | −2 | −1 | 0 | +1 | +2 | >+2 | mi | M | VM | ||
Ampicillin (138) | 0.0 | 0.0 | 2.1 | 97.8 | 0.0 | 0.0 | 0.0 | 100.0 | 0.7 | 0.0 | 0.0 |
Amoxicillin-clavulanate (138) | 0.0 | 0.7 | 7.9 | 85.5 | 3.6 | 1.4 | 0.7 | 97.1 | 5.1 | 1.0 | 0.0 |
Ticarcillin (138) | 1.4 | 0.7 | 3.6 | 93.5 | 0.7 | 0.0 | 0.0 | 97.8 | 3.6 | 0.0 | 0.0 |
Cefazolin (138) | 1.4 | 0.7 | 0.7 | 93.5 | 2.2 | 1.4 | 0.0 | 96.4 | 2.9 | 0.0 | 6.6 |
Cefuroxime (138) | 0.0 | 1.4 | 2.8 | 92.0 | 2.1 | 0.7 | 0.7 | 97.1 | 3.6 | 0.0 | 0.0 |
Cefoxitin (138) | 0.0 | 0.0 | 0.7 | 94.2 | 4.3 | 0.7 | 0.0 | 99.3 | 2.2 | 0.0 | 0.0 |
Cefotaxime (138) | 0.0 | 1.4 | 0.0 | 92.0 | 5.7 | 0.7 | 0.0 | 97.8 | NA | NA | NA |
Ceftazidime (138) | 0.0 | 0.0 | 0.0 | 93.5 | 5.1 | 1.4 | 0.0 | 98.5 | 0.7 | 0.0 | 0.0 |
Aztreonam (138) | 1.4 | 0.7 | 2.2 | 85.5 | 6.5 | 2.9 | 0.7 | 94.2 | 0.7 | 0.7 | 33.3 |
Cefepime (138) | 0.0 | 2.1 | 2.9 | 90.6 | 2.9 | 0.7 | 0.7 | 96.4 | 0.7 | 0.0 | 0.0 |
Meropenem (138) | 0.0 | 0.0 | 0.0 | 98.5 | 1.4 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 0.0 |
Imipenem (138) | 0.0 | 0.7 | 2.1 | 71.0 | 11.0 | 5.8 | 9.4 | 84.0 | 1.4 | 0.7 | 0.0 |
Gentamicin (138) | 0.0 | 0.0 | 1.4 | 95.0 | 0.7 | 2.9 | 0.0 | 97.1 | 0.0 | 0.0 | 0.0 |
Tobramycin (138) | 0.0 | 0.7 | 0.7 | 94.2 | 2.8 | 1.4 | 0.0 | 97.8 | 4.3 | 0.0 | 0.0 |
Amikacin (138) | 0.7 | 0.0 | 2.8 | 92.0 | 2.8 | 1.4 | 0.0 | 97.8 | NA | NA | NA |
Nalidixic acid (138) | 0.0 | 0.0 | 0.0 | 97.1 | 0.7 | 2.1 | 0.0 | 97.8 | 0.0 | 0.0 | 0.0 |
Ciprofloxacin (138) | 0.0 | 0.0 | 2.2 | 85.5 | 4.3 | 0.7 | 7.2 | 92.0 | 0.7 | 0.9 | 0.0 |
Co-trimoxazole (138) | 0.0 | 0.0 | 0.0 | 94.9 | 2.1 | 2.9 | 0.0 | 97.1 | 0.0 | 4.8 | 0.0 |
Total (2,484) | 0.3 | 0.5 | 1.8 | 91.8 | 3.2 | 1.5 | 1.1 | 96.6 | 1.7 | 0.5 | 0.9 |